Literature DB >> 33440660

Risk Factors for the Acquisition of Enterococcus faecium Infection and Mortality in Patients with Enterococcal Bacteremia: A 5-Year Retrospective Analysis in a Tertiary Care University Hospital.

Atsushi Uda1,2, Katsumi Shigemura1,3,4, Koichi Kitagawa3,5, Kayo Osawa6, Kenichiro Onuma1,7, Yonmin Yan4, Tatsuya Nishioka2, Masato Fujisawa4, Ikuko Yano2, Takayuki Miyara1.   

Abstract

The incidence of bacteremia caused by Enterococcus faecium, which is highly resistant to multiple antibiotics, is increasing in Japan. However, risk factors for the acquisition of E. faecium infection and mortality due to enterococcal bacteremia are not well known. We compared demographic, microbiological, and clinical characteristics using a Cox regression model and univariate analysis. We performed a multivariate analysis to identify risk factors for patients treated between 2014 and 2018. Among 186 patients with enterococcal bacteremia, two groups included in the Kaplan-Meier analysis (E. faecalis (n = 88) and E. faecium (n = 94)) showed poor overall survival in the E. faecium group (HR: 1.92; 95% confidence interval: 1.01-3.66; p = 0.048). The median daily antibiotic cost per patient in the E. faecium group was significantly higher than that in the E. faecalis group ($23 ($13-$34) vs. $34 ($22-$58), p < 0.001). E. faecium strains were more frequently identified with previous use of antipseudomonal penicillins (OR = 4.04, p < 0.001) and carbapenems (OR = 3.33, p = 0.003). Bacteremia from an unknown source (OR = 2.79, p = 0.025) and acute kidney injury (OR = 4.51, p = 0.004) were associated with higher risks of 30-day mortality in patients with enterococcal bacteremia. Therefore, clinicians should provide improved medical management, with support from specialized teams such as those assisting antimicrobial stewardship programs.

Entities:  

Keywords:  antimicrobial stewardship; bacteremia; enterococcal; epidemiology; mortality; risk factors

Year:  2021        PMID: 33440660      PMCID: PMC7826794          DOI: 10.3390/antibiotics10010064

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  32 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins.

Authors:  Atsushi Uda; Takeshi Kimura; Sho Nishimura; Kei Ebisawa; Goh Ohji; Mari Kusuki; Mariko Yahata; Rie Izuta; Tomoyuki Sakaue; Tatsuya Nakamura; Chihiro Koike; Issei Tokimatsu; Ikuko Yano; Kentaro Iwata; Takayuki Miyara
Journal:  Infection       Date:  2019-10-11       Impact factor: 3.553

3.  Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.

Authors:  K S Kaye; S Cosgrove; A Harris; G M Eliopoulos; Y Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia.

Authors:  F J Caballero-Granado; B Becerril; L Cuberos; M Bernabeu; J M Cisneros; J Pachón
Journal:  Clin Infect Dis       Date:  2001-02-07       Impact factor: 9.079

5.  Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Authors:  Ravina Kullar; Susan L Davis; Donald P Levine; Michael J Rybak
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

6.  Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002).

Authors:  Adam N Treitman; Paul R Yarnold; John Warren; Gary A Noskin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  Acute renal failure in critically ill patients: a multinational, multicenter study.

Authors:  Shigehiko Uchino; John A Kellum; Rinaldo Bellomo; Gordon S Doig; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Claudio Ronco
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

8.  Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria.

Authors:  Patrick D Mauldin; Cassandra D Salgado; Ida Solhøj Hansen; Darshana T Durup; John A Bosso
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

9.  Incidence, clinical characteristics, and outcomes of nosocomial Enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study.

Authors:  Yangyang Zhang; Mingmei Du; Yan Chang; Liang-An Chen; Qing Zhang
Journal:  Antimicrob Resist Infect Control       Date:  2017-07-04       Impact factor: 4.887

Review 10.  Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review.

Authors:  Justin Tenney; Nicholas Hudson; Hazar Alnifaidy; Justin Ting Cheung Li; Kathy Harriet Fung
Journal:  Saudi Pharm J       Date:  2018-02-09       Impact factor: 4.330

View more
  1 in total

1.  Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project.

Authors:  Marco Mussa; Pedro María Martínez Pérez-Crespo; Luis Eduardo Lopez-Cortes; Pilar Retamar-Gentil; Adrián Sousa-Dominguez; Ane Josune Goikoetxea-Aguirre; José María Reguera-Iglesias; Eva León Jiménez; Isabel Fernández-Natal; Carlos Armiñanzas-Castillo; Lucía Boix-Palop; Jordi Cuquet-Pedragosa; Miguel Ángel Morán Rodríguez; Jonathan Fernandez-Suarez; Alfonso Del Arco-Jiménez; Alfredo Jóver-Saenz; Alberto Bahamonde-Carrasco; Fátima Galan-Sanchez; Juan Manuel Sánchez-Calvo; Alejandro Smithson-Amat; David Vinuesa-García; Antonio Sánchez-Porto; Inmaculada López-Hernández; Jesús Rodríguez-Baño
Journal:  Microbiol Spectr       Date:  2022-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.